GNPX News and Press, Genprex Inc. From 05/28/19

Gene therapy could help overcome barriers that currently stand in the way of a cure for cancer Genprex is developing innovative, gene-based approaches toward the treatment of cancer, specifically non-small cell lung cancer Clinical trials so far have yielded encouraging data regarding t...

Genprex Inc. (NASDAQ: GNPX) , a clinical-stage gene-therapy company, this morning announced that it will be presenting at the upcoming Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum at the Waldorf Astoria Chicago on May 31, 2019. Per the update, Genprex President and COO Julie...

Genprex, Inc. (NASDAQ: GNPX ), a clinical-stage gene therapy company, today announced it will be presenting at the upcoming Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum at the Waldorf Astoria Chicago on May 31, 2019. Taking place on the first day of ASCO, the 5th Ann...

Genprex (NASDAQ: GNPX) is a clinical-stage, gene-therapy company focused on the advancement of its lead drug candidate, Oncoprex(TM) immunogene therapy. Oncoprex is an investigational therapy for non-small cell lung cancer (“NSCLC”). An article discussing the company reads, &#x...

NEW YORK, May 09, 2019 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – Genprex Inc. (NASDAQ:GNPX) announces the availability of a NetworkNewsAudio publication titled, “New Gene Therapies Hold Out Promise for Patients.” To hear the NetworkNewsWire Audio version, v...

Preclinical and clinical data indicate that Oncoprex immunogene therapy may be effective alone or in combination with targeted small molecule therapies; pre-clinical data also indicate potential effectiveness in combination with immunotherapies Lung cancer is the second-most common cancer...

Clinical-stage, gene-therapy company Genprex (NASDAQ: GNPX) this morning announced that it has retained the services of leading pharmaceutical branding agency, Addison Whitney, representing the next step toward commercialization of its lead drug candidate. Utilizing its 28-year history, Addi...

Genprex takes next steps toward identifying drug name for future commercialization Genprex, Inc. (NASDAQ: GNPX ), a clinical-stage gene therapy company, today announced that it has taken a significant step toward commercialization of its lead drug candidate by retaining the service...

NEW YORK, May 08, 2019 (GLOBE NEWSWIRE) -- via NetworkWire — Genprex Inc. (NASDAQ:GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company for private and public entities. To view the full pu...

NetworkNewsWire Editorial Coverage : Gene therapies are gaining growing attention within the medical sector. Gene therapies help restore or replace the body’s damaged or missing genes. Groundbreaking treatments can stop the spread of cancer cells, cause cancer cells to die. G...